Company / R&D Expense
Xeris Biopharma Holdings, Inc. R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$31.2M
FY2025
5-year range
$22.3M / $31.2M
FY2021-FY2025
Trend
+21.9%
vs FY2024
Sector context
#191 of 210
Health Care
What the data says
Among 210 Health Care companies, Xeris Biopharma Holdings, Inc. is in the bottom 9% for r&d expense. Improved from $22M to $31M over the past 2 years.
Based on SEC 10-K filings.
$31M in FY2025 with a 5-year CAGR of +8.3%.
Improved from $22M to $31M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +7.4%
- 5-Year CAGR
- +8.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 210This company $31.2M Sector average $644.1M
▼
-95.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +8.3%, indicating consistent growth.
- In FY2025, r&d expense increased 21.9% year-over-year.
- Ranks #191 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $31.2M | +21.9% |
| FY2024 | $25.6M | +14.4% |
| FY2023 | $22.3M | -11.2% |
| FY2022 | $25.2M | +0.0% |
| FY2021 | $25.2M | +20.3% |
| FY2020 | $20.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026